Sorry what am I missing - where is the data ?, page-3

Refer last few paras of the ASX release. I assume that they have completed the trial and have the data in hand. If this is the case my call is that the ASX may request a trading halt until the data is released otherwise there's a real risk of the market not being 'fully informed' as per the LRs. BIT directors cannot rely on the carve out here under the LR's. Just IMO.

The Directors of BIT infer efficacy in the ASX release and this needs to be substantiated and done so in the context against the primary end points of the trial, no more no less !

"Preliminary analysis of the safety data has shown that BIT225 was well tolerated at the 200mg once daily dose, with no severe adverse events or withdrawals.

Analysis of the trial data is ongoing. The Company aims to present detailed data at scientific conferences and to potential commercial partners in late 2018/early 2019."

ASX LR's stipulate that you cant sit on data as a continuous disclosing entity for convenience to release it at a conference - particularly if the Directors have made a release to the market inferring efficacy AND that has led to a demonstrable increase in share price and trading volumes.

Caveat emptor